Related Experiment Videos
Sulphinpyrazone and renal function following myocardial infarction
European Journal of Clinical Pharmacology
|January 1, 1983
Summary
Sulphinpyrazone effectively increased uric acid excretion and lowered plasma urate levels in patients recovering from acute myocardial infarction. The drug did not impair renal function, suggesting it is safe for this patient group.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) can lead to renal complications.
- Assessing the renal safety of medications used post-AMI is crucial.
Purpose of the Study:
- To evaluate the effects of sulphinpyrazone on renal excretory function in patients following uncomplicated AMI.
- To determine if sulphinpyrazone is contraindicated in the early phase after AMI.
Main Methods:
- A double-blind, placebo-controlled, randomized trial.
- 28 patients with plasma urea < 10 mmol/l, 2-28 days post-AMI.
- Assessed renal function with incremental and full doses of sulphinpyrazone.
Main Results:
- Sulphinpyrazone increased uric acid excretion and decreased plasma urate concentrations.
- No evidence of reduced glomerular filtration rate (GFR).
- No signs of renal tubular damage were observed.
Conclusions:
- Sulphinpyrazone, at the studied doses, does not appear to impair renal excretory function in patients early after AMI.
- The findings suggest sulphinpyrazone is not contraindicated in this population, even with moderate blood urea elevation.